Bernie Sanders Pushes for Cheaper Ozempic Amid Medicare Price Negotiations

Senator Sanders claims generic versions of the diabetes drug could be sold for under $100 per month, as Novo Nordisk faces scrutiny over high U.S. prices.

Senator Bernie Sanders announced that major generic drugmakers are prepared to offer Ozempic for less than $100 per month.
Novo Nordisk's CEO is scheduled to testify before the Senate Committee on Health, Education, Labor, and Pensions next week regarding the drug's pricing.
Ozempic, with a current U.S. list price of approximately $935 per month, is expected to be included in Medicare's 2027 price negotiations.
The Inflation Reduction Act allows Medicare to negotiate drug prices, with the next round of negotiations set to begin in February 2025.
President Biden and other officials have criticized Novo Nordisk for charging significantly higher prices in the U.S. compared to other countries.